Paola M. V. Rancoita
Vita-Salute San Raffaele University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paola M. V. Rancoita.
Blood | 2009
Urban Novak; Andrea Rinaldi; Ivo Kwee; Subhadra V. Nandula; Paola M. V. Rancoita; Mara Compagno; Michaela Cerri; Davide Rossi; Vundavalli V. Murty; Emanuele Zucca; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Govind Bhagat; Francesco Bertoni
Unique and shared cytogenetic abnormalities have been documented for marginal zone lymphomas (MZLs) arising at different sites. Recently, homozygous deletions of the chromosomal band 6q23, involving the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) gene, a negative regulator of NF-kappaB, were described in ocular adnexal MZL, suggesting a role for A20 as a tumor suppressor in this disease. Here, we investigated inactivation of A20 by DNA mutations or deletions in a panel of extranodal MZL (EMZL), nodal MZL (NMZL), and splenic MZL (SMZL). Inactivating mutations encoding truncated A20 proteins were identified in 6 (19%) of 32 MZLs, including 2 (18%) of 11 EMZLs, 3 (33%) of 9 NMZLs, and 1 (8%) of 12 SMZLs. Two additional unmutated nonsplenic MZLs also showed monoallelic or biallelic A20 deletions by fluorescent in situ hybridization (FISH) and/or SNP-arrays. Thus, A20 inactivation by either somatic mutation and/or deletion represents a common genetic aberration across all MZL subtypes, which may contribute to lymphomagenesis by inducing constitutive NF-kappaB activation.
Blood | 2011
Andrea Rinaldi; Michael Mian; Ekaterina Chigrinova; Luca Arcaini; Govind Bhagat; Urban Novak; Paola M. V. Rancoita; Cassio Polpo de Campos; Francesco Forconi; Randy D. Gascoyne; Fabio Facchetti; Maurilio Ponzoni; Silvia Govi; Andrés J.M. Ferreri; Manuela Mollejo; Miguel A. Piris; Luca Baldini; Jean Soulier; Catherine Thieblemont; Vincenzo Canzonieri; Valter Gattei; Roberto Marasca; Silvia Franceschetti; Gianluca Gaidano; Alessandra Tucci; Silvia Uccella; Maria Grazia Tibiletti; Stephan Dirnhofer; Claudio Tripodo; Claudio Doglioni
Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes (extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and splenic MZLs). Nevertheless, the relationship between the subtypes is still unclear. We performed a comprehensive analysis of genomic DNA copy number changes in a very large series of MZL cases with the aim of addressing this question. Samples from 218 MZL patients (25 nodal, 57 MALT, 134 splenic, and 2 not better specified MZLs) were analyzed with the Affymetrix Human Mapping 250K SNP arrays, and the data combined with matched gene expression in 33 of 218 cases. MALT lymphoma presented significantly more frequently gains at 3p, 6p, 18p, and del(6q23) (TNFAIP3/A20), whereas splenic MZLs was associated with del(7q31), del(8p). Nodal MZLs did not show statistically significant differences compared with MALT lymphoma while lacking the splenic MZLs-related 7q losses. Gains of 3q and 18q were common to all 3 subtypes. del(8p) was often present together with del(17p) (TP53). Although del(17p) did not determine a worse outcome and del(8p) was only of borderline significance, the presence of both deletions had a highly significant negative impact on the outcome of splenic MZLs.
Blood | 2013
Ekaterina Chigrinova; Andrea Rinaldi; Ivo Kwee; Davide Rossi; Paola M. V. Rancoita; Jonathan C. Strefford; David Oscier; Kostas Stamatopoulos; Theodora Papadaki; Françoise Berger; Ken H. Young; Fiona Murray; Richard Rosenquist; Timothy C. Greiner; Wing C. Chan; Ester Orlandi; Marco Lucioni; Roberto Marasca; Giorgio Inghirami; Marco Ladetto; Francesco Forconi; Sergio Cogliatti; Hana Votavova; Steven H. Swerdlow; Stephan Stilgenbauer; Miguel A. Piris; András Matolcsy; Dominic V. Spagnolo; Eugene Nikitin; Alberto Zamò
Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia (CLL). Although RS, usually represented by the histologic transformation to a diffuse large B-cell lymphoma (DLBCL), is associated with a very poor outcome, especially when clonally related to the preexisting CLL, the mechanisms leading to RS have not been clarified. To better understand the pathogenesis of RS, we analyzed a series of cases including 59 RS, 28 CLL phase of RS, 315 CLL, and 127 de novo DLBCL. RS demonstrated a genomic complexity intermediate between CLL and DLBCL. Cell-cycle deregulation via inactivation of TP53 and of CDKN2A was a main mechanism in the histologic transformation from CLL phase, being present in approximately one half of the cases, and affected the outcome of the RS patients. A second major subgroup was characterized by the presence of trisomy 12 and comprised one third of the cases. Although RS shared some of the lesions seen in de novo DLBCL, its genomic profile was clearly separate. The CLL phase preceding RS had not a generalized increase in genomic complexity compared with untransformed CLL, but it presented clear differences in the frequency of specific genetic lesions.
The Lancet | 2016
Maria Sessa; Laura Lorioli; Francesca Fumagalli; Serena Acquati; Daniela Redaelli; Cristina Baldoli; Sabrina Canale; Ignazio Diego Lopez; Francesco Morena; Andrea Calabria; Rossana Fiori; Paolo Silvani; Paola M. V. Rancoita; Michela Gabaldo; Fabrizio Benedicenti; Gigliola Antonioli; Andrea Assanelli; Maria Pia Cicalese; Ubaldo Del Carro; Maria Grazia Natali Sora; Sabata Martino; Angelo Quattrini; Eugenio Montini; Clelia Di Serio; Fabio Ciceri; Maria Grazia Roncarolo; Alessandro Aiuti; Luigi Naldini; Alessandra Biffi
BACKGROUND Metachromatic leukodystrophy (a deficiency of arylsulfatase A [ARSA]) is a fatal demyelinating lysosomal disease with no approved treatment. We aimed to assess the long-term outcomes in a cohort of patients with early-onset metachromatic leukodystrophy who underwent haemopoietic stem-cell gene therapy (HSC-GT). METHODS This is an ad-hoc analysis of data from an ongoing, non-randomised, open-label, single-arm phase 1/2 trial, in which we enrolled patients with a molecular and biochemical diagnosis of metachromatic leukodystrophy (presymptomatic late-infantile or early-juvenile disease or early-symptomatic early-juvenile disease) at the Paediatric Clinical Research Unit, Ospedale San Raffaele, in Milan. Trial participants received HSC-GT, which consisted of the infusion of autologous HSCs transduced with a lentiviral vector encoding ARSA cDNA, after exposure-targeted busulfan conditioning. The primary endpoints of the trial are safety (toxicity, absence of engraftment failure or delayed haematological reconstitution, and safety of lentiviral vector-tranduced cell infusion) and efficacy (improvement in Gross Motor Function Measure [GMFM] score relative to untreated historical controls, and ARSA activity, 24 months post-treatment) of HSC-GT. For this ad-hoc analysis, we assessed safety and efficacy outcomes in all patients who had received treatment and been followed up for at least 18 months post-treatment on June 1, 2015. This trial is registered with ClinicalTrials.gov, number NCT01560182. FINDINGS Between April, 2010, and February, 2013, we had enrolled nine children with a diagnosis of early-onset disease (six had late-infantile disease, two had early-juvenile disease, and one had early-onset disease that could not be definitively classified). At the time of analysis all children had survived, with a median follow-up of 36 months (range 18-54). The most commonly reported adverse events were cytopenia (reported in all patients) and mucositis of different grades of severity (in five of nine patients [grade 3 in four of five patients]). No serious adverse events related to the medicinal product were reported. Stable, sustained engraftment of gene-corrected HSCs was observed (a median of 60·4% [range 14·0-95·6] lentiviral vector-positive colony-forming cells across follow-up) and the engraftment level was stable during follow-up; engraftment determinants included the duration of absolute neutropenia and the vector copy number of the medicinal product. A progressive reconstitution of ARSA activity in circulating haemopoietic cells and in the cerebrospinal fluid was documented in all patients in association with a reduction of the storage material in peripheral nerve samples in six of seven patients. Eight patients, seven of whom received treatment when presymptomatic, had prevention of disease onset or halted disease progression as per clinical and instrumental assessment, compared with historical untreated control patients with early-onset disease. GMFM scores for six patients up to the last follow-up showed that gross motor performance was similar to that of normally developing children. The extent of benefit appeared to be influenced by the interval between HSC-GT and the expected time of disease onset. Treatment resulted in protection from CNS demyelination in eight patients and, in at least three patients, amelioration of peripheral nervous system abnormalities, with signs of remyelination at both sites. INTERPRETATION Our ad-hoc findings provide preliminary evidence of safety and therapeutic benefit of HSC-GT in patients with early-onset metachromatic leukodystrophy who received treatment in the presymptomatic or very early-symptomatic stage. The results of this trial will be reported when all 20 patients have achieved 3 years of follow-up. FUNDING Italian Telethon Foundation and GlaxoSmithKline.
British Journal of Haematology | 2012
Annarita Conconi; Carlotta Ponzio; Chiara Lobetti-Bodoni; Maddalena Motta; Paola M. V. Rancoita; Anastasios Stathis; Alden Moccia; Luca Mazzucchelli; Francesco Bertoni; Michele Ghielmini; Franco Cavalli; Emanuele Zucca
Histological transformation (HT) into diffuse large B‐cell lymphoma (DLBCL) was documented in 37 of the 281 (13%; 95% CI, 9–18) follicular lymphoma (FL) patients treated at our institute from 1979 to 2007. HT occurred at a median of 2·75 years from initial FL diagnosis and HT rate was 15% at 10 years and 26% at 14 years, with a plateau from that point onward. Patients with bulky or extranodal disease, or those diagnosed before 1990 had a significantly higher risk of HT. When initial treatment strategies were taken into account, a reduced HT risk was seen in the patients initially managed with a ‘watch and wait’ policy, while the risk appeared significantly increased in the small subset of 18 patients initially managed with rituximab plus chemotherapy (P = 0·0005). HT was associated with a significantly shorter cause‐specific survival (P = 0·0002). Predictors of survival after HT were the Follicular Lymphoma International Prognostic Index at diagnosis, as well as age and performance status at the time of HT. Our data confirm the adverse clinical outcome of FL after HT. In keeping with previous isolated reports, our findings suggest that there is a subgroup of patients in whom HT may not occur.
British Journal of Haematology | 2008
Francesco Forconi; Andrea Rinaldi; Ivo Kwee; Elisa Sozzi; Donatella Raspadori; Paola M. V. Rancoita; Marta Scandurra; Davide Rossi; Clara Deambrogi; Daniela Capello; Emanuele Zucca; Daniela Marconi; Riccardo Bomben; Valter Gattei; Francesco Lauria; Gianluca Gaidano; Francesco Bertoni
Deletion of 17p (TP53) identifies a rare subset of chronic lymphocytic leukaemia (17p‐ CLL) with aggressive behaviour. Genome‐wide DNA‐profiling was performed to investigate 18 patients with 17p‐ CLL. All cases had multiple copy‐number (CN) changes. Among the several recurrent CN changes identified, 8q24.13‐q24.1‐gain (MYC), 8p‐loss (TNFRSF10A/B, also known as TRAIL1/2) and 2p16.1‐p14‐gain (REL/BCL11A) appeared frequently represented. 8p‐loss and 2p16.1‐p14‐gain also appeared clinically relevant and predicted significant shorter time from diagnosis to treatment (8p‐loss) and overall survival (8p‐loss and 2p16.1‐p14‐gain, P < 0·05). These observations document a highly unstable genome in 17p‐ CLL and suggest that additional genes outside the TP53 locus may be important for tumour behaviour.
British Journal of Haematology | 2010
Daniela Capello; Marta Scandurra; Giulia Poretti; Paola M. V. Rancoita; Michael Mian; Annunziata Gloghini; Clara Deambrogi; Maurizio Martini; Davide Rossi; Timothy C. Greiner; Wing C. Chan; Maurilio Ponzoni; S. Moreno; Miguel A. Piris; Vincenzo Canzonieri; Michele Spina; Umberto Tirelli; Giorgio Inghirami; Andrea Rinaldi; Emanuele Zucca; Riccardo Dalla Favera; Franco Cavalli; Luigi Maria Larocca; Ivo Kwee; Antonino Carbone; Gianluca Gaidano; Francesco Bertoni
Non‐Hodgkin lymphomas (NHL) represent a frequent complication of human immunodeficiency virus (HIV) infection. To elucidate HIV‐NHL pathogenesis, we performed a genome‐wide DNA profiling based on a single nucleotide polymorphism‐based microarray comparative genomic hybridization in 57 HIV‐lymphomas and, for comparison, in 105 immunocompetent diffuse large B‐cell lymphomas (IC‐DLBCL). Genomic complexity varied across HIV‐NHL subtypes. HIV‐Burkitt lymphoma showed a significantly lower number of lesions than HIV‐DLBCL (P = 0·032), whereas the median number of copy number changes was significantly higher in Epstein–Barr virus negative (EBV‐) HIV‐DLBCL (42·5, range 8–153) compared to EBV+ cases (22; range 3–41; P = 0·029). Compared to IC‐DLBCL, HIV‐DLBCL displayed a distinct genomic profile with no gains of 18q and specific genetic lesions. Fragile sites‐associated genes, including FHIT (FRA3B), WWOX (FRA16D), DCC (FRA18B) and PARK2 (FRA6E) were frequently inactivated in HIV‐NHL by interstitial deletions, and a significantly higher prevalence of FHIT alterations was observed in HIV‐DLBCL compared to IC‐DLBCL. The same genes involved by fragile site deletions were also frequently affected by aberrant methylation of regulative regions.
Journal of Neurology | 2014
Luigi Ferini-Strambi; Wolfgang H. Oertel; Yves Dauvilliers; Ronald B. Postuma; Sara Marelli; Alex Iranzo; Isabelle Arnulf; Högl Birgit; Raffaele Manni; Tomoyuki Miyamoto; Maria Livia Fantini; Monica Puligheddu; Poul Jennum; Karel Sonka; Joan Santamaria; Marco Zucconi; Paola M. V. Rancoita; S. Leu-Semenescu; Birgit Frauscher; M. Terzaghi; Masayuki Miyamoto; Marcus M. Unger; Karin Stiasny-Kolster; Alex Desautels; Christina Wolfson; Amélie Pelletier; Jacques Montplaisir
Patients with idiopathic REM sleep behavior disorder (iRBD) are at very high risk of developing neurodegenerative synucleinopathies, which are disorders with prominent autonomic dysfunction. Several studies have documented autonomic dysfunction in iRBD, but large-scale assessment of autonomic symptoms has never been systematically performed. Patients with polysomnography-confirmed iRBD (318 cases) and controls (137 healthy volunteers and 181 sleep center controls with sleep diagnoses other than RBD) were recruited from 13 neurological centers in 10 countries from 2008 to 2011. A validated scale to study the disorders of the autonomic nervous system in Parkinsons disease (PD) patients, the SCOPA-AUT, was administered to all the patients and controls. The SCOPA-AUT consists of 25 items assessing the following domains: gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual dysfunction. Our results show that compared to control subjects with a similar overall age and sex distribution, patients with iRBD experience significantly more problems with gastrointestinal, urinary, and cardiovascular functioning. The most prominent differences in severity of autonomic symptoms between our iRBD patients and controls emerged in the gastrointestinal domain. Interestingly, it has been reported that an altered gastrointestinal motility can predate the motor phase of PD. The cardiovascular domain SCOPA-AUT score in our study in iRBD patients was intermediate with respect to the scores reported in PD patients by other authors. Our findings underline the importance of collecting data on autonomic symptoms in iRBD. These data may be used in prospective studies for evaluating the risk of developing neurodegenerative disorders.
Blood | 2013
Michela Boi; Andrea Rinaldi; Ivo Kwee; Paola Bonetti; Maria Todaro; Fabrizio Tabbò; Roberto Piva; Paola M. V. Rancoita; András Matolcsy; Botond Timár; Thomas Tousseyn; Socorro M. Rodríguez-Pinilla; Miguel A. Piris; Sílvia Beà; Elias Campo; Govind Bhagat; Steven H. Swerdlow; Andreas Rosenwald; Maurilio Ponzoni; Ken H. Young; Pier Paolo Piccaluga; Reinhard Dummer; Stefano Pileri; Emanuele Zucca; Giorgio Inghirami; Francesco Bertoni
Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma that can present as a systemic or primary cutaneous disease. Systemic ALCL represents 2% to 5% of adult lymphoma but up to 30% of all pediatric cases. Two subtypes of systemic ALCL are currently recognized on the basis of the presence of a translocation involving the anaplastic lymphoma kinase ALK gene. Despite considerable progress, several questions remain open regarding the pathogenesis of both ALCL subtypes. To investigate the molecular pathogenesis and to assess the relationship between the ALK(+) and ALK(-) ALCL subtypes, we performed a genome-wide DNA profiling using high-density, single nucleotide polymorphism arrays on a series of 64 cases and 7 cell lines. The commonest lesions were losses at 17p13 and at 6q21, encompassing the TP53 and PRDM1 genes, respectively. The latter gene, coding for BLIMP1, was inactivated by multiple mechanisms, more frequently, but not exclusively, in ALK(-)ALCL. In vitro and in vivo experiments showed that that PRDM1 is a tumor suppressor gene in ALCL models, likely acting as an antiapoptotic agent. Losses of TP53 and/or PRDM1 were present in 52% of ALK(-)ALCL, and in 29% of all ALCL cases with a clinical implication.
European Urology | 2014
C. Cozzarini; C. Fiorino; C. Deantoni; Alberto Briganti; A. Fodor; Mariangela La Macchia; Barbara Noris Chiorda; Paola M. V. Rancoita; Nazareno Suardi; F. Zerbetto; R. Calandrino; Francesco Montorsi; Nadia Di Muzio
BACKGROUND Dose escalation and hypofractionation may have a role in postprostatectomy radiotherapy (RT), but at the risk of increasing urinary toxicity. OBJECTIVE To address predictors of severe (Grade ≥3) late urinary toxicities (LGUTOX3) after postoperative irradiation. DESIGN, SETTING, AND PARTICIPANTS A single-institution cohort of 1176 patients treated between 1993 and 2010 with adjuvant or salvage RT was analyzed. A total of 929 patients underwent conventionally fractionated (CF) RT (1.8 Gy per fraction; median dose to the prostatic bed: 70.2 Gy) with nonconformal RT (n=169), three-dimensional conformal RT (n=657), or intensity-modulated RT (n=103) technique, while 247 patients received hypofractionated helical TomoTherapy (median: 2.50 Gy per fraction) at the following doses: 117 patients at 65.8 Gy (2.35 Gy in 28 fractions), 80 patients at a median of 71.4 Gy (2.5-2.6 Gy in 28 fractions), and 50 patients at 58 Gy in 20 fractions. Total doses were converted into 2 Gy-equivalent doses (EQD2) following the linear quadratic model taking α/β=5. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Univariable and multivariable Cox regression models tested the relationship between clinicodosimetric variables and the risk of LGUTOX3 retrospectively, graded according to Common Terminology Criteria for Adverse Events v.4.0. RESULTS AND LIMITATIONS After a median follow-up of 98 mo, the 5-yr risk of LGUTOX3 was 6.9% and 18.1% in the CF and hypofractionated cohorts, respectively. At univariable analysis, the risk of LGUTOX3 was predicted by dose per fraction (hazard ratio [HR]: 2.96), acute Grade ≥2 toxicity (HR: 2.37), EQD2, pT4, and year of irradiation. At multivariable analyses, acute Grade ≥2 toxicity and dose per fraction independently predicted LGUTOX3 in the population, while an interaction analysis indicated a predictive role of hypertension in the hypofractionated cohort only. These findings are limited by their retrospective nature. CONCLUSIONS In the postprostatectomy setting, the logistic convenience of hypofractionation should be carefully balanced against the risk of severe late urinary sequelae. PATIENT SUMMARY This study investigated the causes of urinary adverse effects after postprostatectomy radiotherapy. Hypofractionation resulted in an increased risk of severe urinary toxicities.